Aquestive Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AQST Nasdaq 2834 https://aquestive.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aquestive Therapeutics Inc

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets - Mar 29th, 2023 12:30 pm
Q4 2022 Aquestive Therapeutics Inc Earnings Call - Mar 9th, 2023 4:43 am
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates - Mar 7th, 2023 10:15 pm
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives - Mar 7th, 2023 9:01 pm
Assertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth - Mar 1st, 2023 3:00 pm
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference - Mar 1st, 2023 1:00 pm
Aquestive Therapeutics (AQST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Feb 28th, 2023 3:00 pm
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET - Feb 22nd, 2023 1:00 pm
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - Feb 21st, 2023 1:00 pm
Assertio (ASRT) to Report Q4 Earnings: What's in the Cards? - Feb 13th, 2023 3:31 pm
When Will Aquestive Therapeutics, Inc. (NASDAQ:AQST) Breakeven? - Jan 27th, 2023 10:51 am
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives - Jan 6th, 2023 1:00 pm
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film) - Dec 22nd, 2022 1:00 pm
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia - Nov 29th, 2022 1:00 pm
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences - Nov 15th, 2022 1:00 pm
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting - Nov 9th, 2022 9:33 pm
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates - Nov 1st, 2022 9:15 pm
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 1st, 2022 8:01 pm
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc. - Oct 27th, 2022 1:05 pm
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc. - Oct 27th, 2022 1:00 pm